A detailed history of Black Rock Inc. transactions in Lexicon Pharmaceuticals, Inc. stock. As of the latest transaction made, Black Rock Inc. holds 9,890,153 shares of LXRX stock, worth $15.8 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
9,890,153
Previous 7,693,277 28.56%
Holding current value
$15.8 Million
Previous $18.5 Million 10.01%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$1.54 - $2.28 $3.38 Million - $5.01 Million
2,196,876 Added 28.56%
9,890,153 $16.6 Million
Q1 2024

May 10, 2024

BUY
$1.3 - $3.58 $894,561 - $2.46 Million
688,124 Added 9.82%
7,693,277 $18.5 Million
Q4 2023

Feb 13, 2024

BUY
$1.0 - $1.53 $350,187 - $535,786
350,187 Added 5.26%
7,005,153 $10.7 Million
Q3 2023

Nov 13, 2023

BUY
$1.06 - $2.33 $292,326 - $642,567
275,780 Added 4.32%
6,654,966 $7.25 Million
Q2 2023

Aug 11, 2023

BUY
$2.15 - $3.49 $1.55 Million - $2.52 Million
722,259 Added 12.77%
6,379,186 $14.6 Million
Q1 2023

May 12, 2023

SELL
$1.99 - $2.68 $389,160 - $524,095
-195,558 Reduced 3.34%
5,656,927 $13.7 Million
Q4 2022

Feb 13, 2023

BUY
$1.8 - $2.56 $166,473 - $236,761
92,485 Added 1.61%
5,852,485 $11.2 Million
Q3 2022

Nov 14, 2022

BUY
$1.94 - $3.43 $2.41 Million - $4.25 Million
1,240,171 Added 27.44%
5,760,000 $13.8 Million
Q2 2022

Aug 12, 2022

BUY
$1.31 - $2.69 $97,040 - $199,267
74,077 Added 1.67%
4,519,829 $8.41 Million
Q1 2022

May 12, 2022

SELL
$1.95 - $3.89 $199,235 - $397,449
-102,172 Reduced 2.25%
4,445,752 $9.29 Million
Q4 2021

Feb 10, 2022

SELL
$3.81 - $6.16 $391,462 - $632,915
-102,746 Reduced 2.21%
4,547,924 $17.9 Million
Q3 2021

Nov 09, 2021

BUY
$3.38 - $5.35 $12,881 - $20,388
3,811 Added 0.08%
4,650,670 $22.4 Million
Q2 2021

Aug 11, 2021

BUY
$4.12 - $5.87 $19.1 Million - $27.3 Million
4,646,859 New
4,646,859 $21.3 Million

Others Institutions Holding LXRX

About LEXICON PHARMACEUTICALS, INC.


  • Ticker LXRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 188,726,000
  • Market Cap $302M
  • Description
  • Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; ...
More about LXRX
Track This Portfolio

Track Black Rock Inc. Portfolio

Follow Black Rock Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.